Technical Analysis for CCCC - C4 Therapeutics, Inc.
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Lower Bollinger Band Walk | Weakness | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Down 5 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
NR7 | Range Contraction | -2.41% | |
Narrow Range Bar | Range Contraction | -2.41% | |
Lower Bollinger Band Walk | Weakness | -2.41% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 20 hours ago |
Down 5% | about 20 hours ago |
Down 3% | about 23 hours ago |
Fell Below Previous Day's Low | about 23 hours ago |
Down 2 % | about 23 hours ago |
Get a Trading Sidekick!
- Earnings date: 10/30/2024
C4 Therapeutics, Inc. Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Disease Treatment Of Cancer Non Small Cell Lung Cancer Melanoma Colorectal Cancer Multiple Myeloma NSCLC Synovial Sarcoma Treatment Of Various Cancers Peripheral T Cell Lymphoma
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 11.88 |
52 Week Low | 1.06 |
Average Volume | 951,472 |
200-Day Moving Average | 6.43 |
50-Day Moving Average | 5.77 |
20-Day Moving Average | 5.44 |
10-Day Moving Average | 5.01 |
Average True Range | 0.45 |
RSI (14) | 28.06 |
ADX | 23.28 |
+DI | 12.28 |
-DI | 36.60 |
Chandelier Exit (Long, 3 ATRs) | 5.17 |
Chandelier Exit (Short, 3 ATRs) | 5.19 |
Upper Bollinger Bands | 6.90 |
Lower Bollinger Band | 3.97 |
Percent B (%b) | 0.03 |
BandWidth | 53.87 |
MACD Line | -0.44 |
MACD Signal Line | -0.24 |
MACD Histogram | -0.2043 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 4.64 | ||||
Resistance 3 (R3) | 4.63 | 4.43 | 4.54 | ||
Resistance 2 (R2) | 4.43 | 4.28 | 4.43 | 4.50 | |
Resistance 1 (R1) | 4.24 | 4.19 | 4.14 | 4.25 | 4.47 |
Pivot Point | 4.04 | 4.04 | 3.99 | 4.04 | 4.04 |
Support 1 (S1) | 3.85 | 3.89 | 3.75 | 3.86 | 3.63 |
Support 2 (S2) | 3.65 | 3.80 | 3.65 | 3.60 | |
Support 3 (S3) | 3.46 | 3.65 | 3.56 | ||
Support 4 (S4) | 3.47 |